iPS cells reprogrammed from primary dendritic cells provide an abundant source of immunostimulatory dendritic cells for use in immunotherapy
Cell types differentiated from induced pluripotent stem cells (iPSCs) are frequently arrested in their development program, more closely resembling a fetal rather than an adult phenotype, potentially limiting their utility for downstream clinical applications. The fetal phenotype of iPSC‐derived den...
Автори: | Horton, C, Davies, TJ, Lahiri, P, Sachamitr, P, Fairchild, PJ |
---|---|
Формат: | Journal article |
Мова: | English |
Опубліковано: |
Wiley
2019
|
Схожі ресурси
Схожі ресурси
-
Cross presentation of antigen by dendritic cells: mechanisms and implications for immunotherapy.
за авторством: Sachamitr, P, та інші
Опубліковано: (2012) -
Towards the rational design of a next-generation dendritic cell vaccine for cancer immunotherapy
за авторством: Bravo, M, та інші
Опубліковано: (2021) -
Directed differentiation of human induced pluripotent stem cells into dendritic cells displaying tolerogenic properties and resembling the CD141+ subset
за авторством: Sachamitr, P, та інші
Опубліковано: (2018) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals
за авторством: Hanif, Javanmard Khameneh
Опубліковано: (2011) -
Enhancement of tolerogenic or immunostimulatory potential of dendritic cells for therapeutic goals.
за авторством: Hanif Javanmard Khameneh
Опубліковано: (2014)